Trihexyphenidyl treatment of clozapine-induced hypersalivation

B. Spivak*, S. Adlersberg, L. Rosen, N. Gonen, R. Mester, A. Weizman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Abstract

The objective of this study was to investigate the efficacy of the anticholinergic agent trihexyphenidyl in the treatment of clozapine-induced hypersalivation. Fourteen chronic schizophrenic patients who exhibited nocturnal hypersalivation during clozapine treatment were coadministered trihexyphenidyl (5-15 mg/day, at bedtime) for 15 days. Salivation was assessed by a single-item 5-point scale. A reduction of 44% in the reported nocturnal hypersalivation was observed after trihexyphenidyl treatment. These results indicate that at least some chronic schizophrenic patients with clozapine-induced nocturnal hypersalivation may benefit from anticholinergic treatment.

Original languageEnglish
Pages (from-to)213-215
Number of pages3
JournalInternational Clinical Psychopharmacology
Volume12
Issue number4
DOIs
StatePublished - 1997

Keywords

  • Clozapine
  • Hypersalivation
  • Trihexyphenidyl

Fingerprint

Dive into the research topics of 'Trihexyphenidyl treatment of clozapine-induced hypersalivation'. Together they form a unique fingerprint.

Cite this